TABLE 3.
PVT-10 and PVT-3 1/RT rmcorr results by day and by study phase.
| Condition | Statistic | Study day |
Study phase |
||||||||||||||
| B2 | SR1 | SR2 | SR3 | SR4 | SR5 | R1 | R2 | R3 | R4 | TSD | ALL | B2-R4 | SR1-SR5 | R1-R4 | TSD | ||
| A | r rm | 0.284 | 0.699 | 0.629 | 0.623 | 0.590 | 0.482 | 0.540 | 0.310 | 0.375 | 0.352 | 0.691 | 0.712 | 0.678 | 0.663 | 0.422 | 0.691 |
| df | 156 | 327 | 368 | 366 | 368 | 182 | 140 | 202 | 162 | 163 | 409 | 3345 | 2894 | 1779 | 793 | 409 | |
| p | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| CI low | 0.129 | 0.627 | 0.543 | 0.539 | 0.523 | 0.328 | 0.391 | 0.146 | 0.232 | 0.189 | 0.633 | 0.690 | 0.650 | 0.632 | 0.357 | 0.633 | |
| CI high | 0.451 | 0.762 | 0.702 | 0.695 | 0.655 | 0.598 | 0.663 | 0.463 | 0.499 | 0.484 | 0.741 | 0.733 | 0.702 | 0.696 | 0.481 | 0.741 | |
| PVT-10 | Mdn (IQR) |
4.03 (0.75) |
3.70 (0.84) |
3.60 (0.80) |
3.50 (0.78) |
3.36 (0.81) |
3.29 (0.87) |
3.65 (0.85) |
3.63 (0.73) |
3.64 (0.69) |
3.62 (0.60) |
3.21 (0.80) |
3.54 (0.84) |
3.58 (0.83) |
3.49 (0.84) |
3.63 (0.72) |
3.21 (0.80) |
| PVT-3 | Mdn (IQR) |
4.31 (0.78) |
4.01 (1.05) |
3.82 (1.14) |
3.76 (1.02) |
3.56 (1.04) |
3.59 (1.09) |
4.13 (0.97) |
3.95 (1.01) |
4.03 (0.93) |
3.92 (0.93) |
3.49 (1.13) |
3.85 (1.08) |
3.91 (1.05) |
3.76 (1.10) |
4.02 (0.98) |
3.49 (1.13) |
|
| |||||||||||||||||
| B2 | TSD | R1 | R2 | R3 | R4 | SR1 | SR2 | SR3 | SR4 | SR5 | ALL | B2-R4 | TSD | R1-R4 | SR1-SR5 | ||
|
| |||||||||||||||||
| B | r rm | 0.305 | 0.676 | 0.408 | 0.376 | 0.370 | 0.526 | 0.747 | 0.744 | 0.691 | 0.691 | 0.609 | 0.808 | 0.784 | 0.676 | 0.466 | 0.737 |
| df | 149 | 388 | 166 | 209 | 167 | 167 | 335 | 377 | 377 | 377 | 186 | 3442 | 1449 | 388 | 838 | 1824 | |
| p | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| CI low | 0.152 | 0.611 | 0.272 | 0.217 | 0.228 | 0.164 | 0.688 | 0.670 | 0.620 | 0.616 | 0.485 | 0.791 | 0.757 | 0.611 | 0.353 | 0.706 | |
| CI high | 0.465 | 0.734 | 0.521 | 0.498 | 0.508 | 0.695 | 0.798 | 0.807 | 0.754 | 0.757 | 0.709 | 0.823 | 0.810 | 0.734 | 0.569 | 0.767 | |
| PVT-10 | Mdn (IQR) |
3.88 (0.74) |
3.48 (0.84) |
3.89 (0.74) |
3.88 (0.78) |
3.90 (0.82) |
3.83 (0.72) |
3.60 (0.80) |
3.55 (0.76) |
3.50 (0.78) |
3.42 (0.84) |
3.45 (0.79) |
3.64 (0.80) |
3.78 (0.78) |
3.48 (0.84) |
3.88 (0.76) |
3.50 (0.81) |
| PVT-3 | Mdn (IQR) |
4.12 (0.97) |
3.61 (1.07) |
4.21 (0.98) |
4.16 (0.95) |
4.23 (0.98) |
4.13 (0.93) |
3.82 (1.03) |
3.75 (0.91) |
3.70 (0.99) |
3.59 (1.02) |
3.60 (0.95) |
3.87 (1.00) |
4.04 (0.95) |
3.61 (1.07) |
4.17 (0.95) |
3.71 (0.99) |
PVT-10 = 10-min Psychomotor Vigilance Test; PVT-3 = 3-min Psychomotor Vigilance Test; 1/RT = response speed; rmcorr = repeated measures correlation; B2 = baseline day 2; SR1-SR5 = sleep restriction days 1 through 5; R1-R4 = recovery days 1 through 4; TSD = total sleep deprivation; ALL = all study days; CI = bootstrapped 95% confidence interval; Mdn = median; IQR = interquartile range.